BioGlow Health review

BioGlow publishes a product catalog with prices and a roughly one-month supply description. It is easier to price than to identify the actual care team: the reviewed pages did not name the assigned clinicians or pharmacies. Payment precedes intake, and the terms allow the company to cancel an inappropriate order. That is not an unconditional clinical-denial refund guarantee; confirm the payment and refund path before ordering.

BioGlow presents cash-pay care across peptides, testosterone, weight loss, sexual health and hair care. Its catalog distinguishes sermorelin, injectable and nasal NAD⁺, testosterone cypionate and enclomiphene. The homepage claims all 50 states, but terms limit service to states where providers are authorized. Terms identify adult eligibility at 18 or older; individual prescribing remains conditional.

The homepage describes buying a medication before completing intake. The peptide page describes intake, labs and a video consultation, with follow-up labs every 8–12 weeks. TRT describes bloodwork and a video visit, with follow-up at six and twelve weeks, then every three to six months. It advertises comprehensive lab monitoring included, but exact charges, testing arrangements and required panels were not established. No individual prescribing clinician or dispensing pharmacy was named in the reviewed pages.

The shop lists sermorelin $259, NAD⁺ injection $279 or nasal spray $179, testosterone cypionate 200 mg/mL at $159 for 1 mL or $199 for 10 mL, and enclomiphene $209. The catalog describes roughly one-month supplies, but vial size does not establish the prescribed duration; confirm dose, full debit and renewal. Terms say payment uses Square, dispensed prescriptions cannot be returned, and refunds for unfulfilled or canceled orders take five to ten business days. An automatic renewal schedule and exact cancellation cutoff were not established.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Confirm the actual formulation and dispensing pharmacy. On the evidence, take it in tiers. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism with thin long-term human outcome data. Injectable and intranasal NAD⁺ have no controlled human outcome trials; the oral precursors NR and NMN are the studied forms, and they raise a biomarker rather than demonstrate an outcome. Injected or inhaled glutathione for skin brightening and detox has very little controlled human evidence. PT-141 (bremelanotide) is the active ingredient of an FDA-approved drug for low desire in premenopausal women; the compounded version and its use in men are off-label. Testosterone cypionate is a well-established therapy for diagnosed hypogonadism that needs ongoing bloodwork and suppresses fertility; enclomiphene is the fertility-sparing alternative, used off-label. Individual results vary.